Structure Therapeutics (GPCR) Change in Acquisitions & Divestments (2022 - 2026)

Structure Therapeutics' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $151.7 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 0.83% year-over-year to $151.7 million in Q1 2026; TTM through Mar 2026 was $631.8 million, a 36.79% increase from a year earlier, with the FY2025 full-year figure at $630.5 million, up 82.82% from the prior year.
• Change in Acquisitions & Divestments grew to $151.7 million in Q1 2026 per GPCR's latest filing, from $146.2 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $195.9 million in Q3 2025 and bottomed at -$92.8 million in Q2 2023.
• The 5-year median for Change in Acquisitions & Divestments is $66.4 million (2024), against an average of $78.8 million.
• Biggest YoY gain for Change in Acquisitions & Divestments was 6954.0% in 2023; the steepest drop was 983.62% in 2023.
• Year by year, Change in Acquisitions & Divestments stood at $19.6 million in 2022, then surged by 190.82% to $57.0 million in 2023, then surged by 190.35% to $165.5 million in 2024, then retreated by 11.68% to $146.2 million in 2025, then increased by 3.79% to $151.7 million in 2026.
• Per Business Quant, the three latest GPCR Change in Acquisitions & Divestments figures stand at $151.7 million (Q1 2026), $146.2 million (Q4 2025), and $195.9 million (Q3 2025).